

Junli Xue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2664868/publications.pdf>

Version: 2024-02-01

14
papers

190
citations

1478505

6
h-index

1125743

13
g-index

19
all docs

19
docs citations

19
times ranked

284
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a rapid and sensitive UPLC-MS/MS assay for simultaneous quantitation of Vorolanib and its metabolite in human plasma and application to a pharmacokinetics study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 199, 114034.	2.8	5
2	WX390, a high-potent PI3K-mTOR dual inhibitor, first-in-human (FIH) phase I study in advanced relapsed or refractory solid tumor, and lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3106-3106.	1.6	0
3	Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 646410.	2.8	6
4	Cell-Friendly Isolation and pH-Sensitive Controllable Release of Circulating Tumor Cells by Fe ₃ O ₄ @CaCO ₃ Nanoplatfrom. <i>Advanced Materials Interfaces</i> , 2021, 8, 2101191.	3.7	6
5	Development of an Autophagy-Based and Stemness-Correlated Prognostic Model for Hepatocellular Carcinoma Using Bulk and Single-Cell RNA-Sequencing. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 743910.	3.7	12
6	Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3638.	1.6	9
7	First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16126-e16126.	1.6	1
8	First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1101-TPS1101.	1.6	10
9	Type 1 β phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer. <i>EBioMedicine</i> , 2019, 44, 375-386.	6.1	19
10	Intrinsic β -catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108921.	5.6	57
11	PIPKI β Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	2.2	26
12	Type 1 β phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF- κ B. <i>Oncotarget</i> , 2017, 8, 42414-42427.	1.8	26
13	Silencing of type 1 β phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion. <i>Oncology Reports</i> , 2017, 38, 253-262.	2.6	3
14	EGFR-induced phosphorylation of type 1 β phosphatidylinositol phosphate kinase promotes pancreatic cancer progression. <i>Oncotarget</i> , 2017, 8, 42621-42637.	1.8	8